Target intelligence / Profile preview

Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L (MT-ND4L)

Target
MT-ND4L
Molecular classification
Enzyme, Oxidoreductase, Respiratory chain complex subunit (Complex I)
01

Overview

Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L (MT-ND4L) is a protein subunit of mitochondrial respiratory chain Complex I, localized in the inner mitochondrial membrane. It is encoded by the mitochondrial genome and forms part of the highly hydrophobic transmembrane core of the Complex I enzyme. MT-ND4L participates in the initial step of the electron transport chain, transferring electrons from NADH to ubiquinone (coenzyme Q10), a process that drives proton translocation and ATP synthesis via oxidative phosphorylation. Mutations in MT-ND4L are pathogenic and cause mitochondrial disorders such as Leber hereditary optic neuropathy and have been linked to metabolic diseases. No drugs are known to specifically target MT-ND4L, but the full complex is sensitive to certain inhibitors and toxins. Dysfunction of this subunit critically impairs mitochondrial bioenergetic capacity, with systemic disease implications.

Other names
NADH-ubiquinone oxidoreductase chain 4LMTND4LNADH dehydrogenase subunit 4LNADH dehydrogenase 4LComplex I, subunit ND4LNADH4LND4LNAD4LNADH-ubiquinone oxidoreductase, subunit ND4L
02

Mechanism of action

Inhibitors of mitochondrial complex I (for the enzyme complex as a whole, not specifically MT-ND4L subunit) lead to disruption of electron transport from NADH to ubiquinone, impairing ATP synthesis (typical for pathogenic mutations; no approved drugs act specifically on MT-ND4L).

03

Biological functions

Electron transport chainOxidative phosphorylationProton translocation across mitochondrial inner membraneATP synthesis
04

Disease associations

Mitochondrial diseaseLeber hereditary optic neuropathy (LHON)Metabolic disorders (including diabetes mellitus and obesity)
05

Safety considerations

Altered function can lead to mitochondrial dysfunction and cellular energy metabolism defectsMutations associated with optic neuropathy and metabolic disease; therapeutic modulation risks impairing cellular energy production systemically
06

Biomarkers

MT-ND4L gene mutations for diagnosis/risk assessment in Leber hereditary optic neuropathyMitochondrial DNA analysis for detecting mutations related to mitochondrial dysfunction

Beyond the preview

Go deeper on Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L (MT-ND4L).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L (MT-ND4L).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call